NO20061168L - Andvendelse av polypeptider av cuperidoxinfamilien ved cancerterapi - Google Patents

Andvendelse av polypeptider av cuperidoxinfamilien ved cancerterapi

Info

Publication number
NO20061168L
NO20061168L NO20061168A NO20061168A NO20061168L NO 20061168 L NO20061168 L NO 20061168L NO 20061168 A NO20061168 A NO 20061168A NO 20061168 A NO20061168 A NO 20061168A NO 20061168 L NO20061168 L NO 20061168L
Authority
NO
Norway
Prior art keywords
treating
cuperidoxin
polypeptides
family
cytotoxic factors
Prior art date
Application number
NO20061168A
Other languages
English (en)
Inventor
Amanda M Chakrabarty
Tapas K Dasgupta
Vasu Punj
Olga Zaborina
Yoshinori Hiraoka
Tohru Yamada
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of NO20061168L publication Critical patent/NO20061168L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/415—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Cytotoksiske faktorer til anvendelse i modulering av celledød og deres anvendelse i fremgangsmåter til behandling av nekrose eller apoptose-relaterte tilstander er beskrevet. Oppfinnelsen angår også fremgangsmåter til identifisering av aktive midler som er nyttige til behandling av tilstander som er relatert til celledød eller ukontrollert vekst. Oppfinneme av foreliggende oppfinnelse har funnet at ulike mikroorganismer produserer ulike cytotoksiske faktorer som har anitcancer-aktivitet. De vesentlig rene cytotoksiske faktorene kan anvendes i en fremgangsmåte til behandling av en infeksjonssykdom eller kreft.
NO20061168A 2003-08-15 2006-03-13 Andvendelse av polypeptider av cuperidoxinfamilien ved cancerterapi NO20061168L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41455003P 2003-08-15 2003-08-15
US10/720,603 US7491394B2 (en) 2001-02-15 2003-11-24 Cytotoxic factors for modulating cell death
PCT/US2004/025982 WO2005018662A1 (en) 2003-08-15 2004-08-10 Use of polypeptides of the cupredoxin family in cancer therapy

Publications (1)

Publication Number Publication Date
NO20061168L true NO20061168L (no) 2006-05-15

Family

ID=34221130

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061168A NO20061168L (no) 2003-08-15 2006-03-13 Andvendelse av polypeptider av cuperidoxinfamilien ved cancerterapi

Country Status (19)

Country Link
US (4) US7491394B2 (no)
EP (2) EP1653990B1 (no)
JP (1) JP2007502818A (no)
KR (1) KR20060098358A (no)
AP (1) AP2006003537A0 (no)
AT (1) ATE470672T1 (no)
AU (1) AU2004266632A1 (no)
BR (1) BRPI0413574A (no)
CA (1) CA2535581A1 (no)
DE (1) DE602004027637D1 (no)
EA (1) EA009897B1 (no)
EC (1) ECSP066422A (no)
GE (1) GEP20105022B (no)
IL (1) IL173576A0 (no)
NO (1) NO20061168L (no)
NZ (1) NZ545355A (no)
OA (1) OA13308A (no)
TN (1) TNSN06059A1 (no)
WO (1) WO2005018662A1 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618939B2 (en) 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US7338766B2 (en) * 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US9096663B2 (en) * 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US9434770B2 (en) * 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
UA97466C2 (ru) 2004-10-07 2012-02-27 Ананда Чакрабарти Транспортирующие соединения - производные купредоксина и способы их применения
US9968685B2 (en) 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EP1888106A4 (en) * 2005-05-20 2009-01-14 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH EPRININ SIGNALING USING CUPREDOXINS
KR20080019615A (ko) * 2005-05-20 2008-03-04 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신과 시토크롬으로 말라리아를 치료하기 위한조성물과 방법
MX2007014599A (es) * 2005-05-20 2008-02-07 Univ Illinois Composiciones y metodos para el tratamiento de infeccion por vih con cupredoxina y citocromo c.
MX2008000993A (es) * 2005-07-19 2008-03-19 Univ Illinois Composiciones y metodos para controlar la angiogenesis con cupredoxinas.
AU2006269879A1 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
US10266868B2 (en) 2006-05-19 2019-04-23 The Board Of Trustees Of The University Of Illinois Compositions for treating HIV infection with cupredoxin and cytochrome C
BRPI0715027A2 (pt) 2006-09-11 2013-05-28 Univ Illinois modificaÇÕes dos peptÍdeos derivados da cupredoxina e seus mÉtodos de utilizaÇço
JP2010503409A (ja) * 2006-09-14 2010-02-04 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ クプレドキシンによって癌を予防する組成物および方法
MX2009005849A (es) * 2006-12-04 2009-08-12 Univ Illinois Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
EP2117573A4 (en) * 2007-01-11 2011-02-16 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING EPHRIN SIGNALING WITH CUPREDOXINES AND MUTANTS THEREOF
KR20090114414A (ko) 2007-02-08 2009-11-03 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신으로 암을 예방하는 조성물과 방법
AU2009294673B2 (en) * 2008-09-18 2014-08-14 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
PT2971039T (pt) 2013-03-14 2020-05-06 Immusoft Corp Métodos para diferenciação e transdução in vitro de células b de memória com vetores virais pseudotipados vsv-g
DK3234107T3 (da) 2014-12-19 2022-10-17 Immusoft Corp B-celler til in vivo-levering af terapeutiske midler
US11136613B2 (en) 2015-04-30 2021-10-05 Board Of Regents, The University Of Texas System Antibacterial polypeptide libraries and methods for screening the same
CN111705026B (zh) * 2020-06-02 2021-11-26 华中农业大学 一种牛支原体Mbov_0280基因突变株及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585644A (en) 1984-06-04 1986-04-29 Phillips Petroleum Company Changing oil tubes in a carbon black reactor
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5827934A (en) * 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
ES2116269T3 (es) 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
DE69333814T2 (de) 1992-03-11 2006-02-02 Powderject Vaccines, Inc., Madison Genetischer impfstoff gegen den immunschwäche virus
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
EP0678034B1 (en) 1993-01-11 1999-05-26 Dana Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5972899A (en) * 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US7084105B2 (en) 2001-02-15 2006-08-01 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7301010B2 (en) 2001-02-15 2007-11-27 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
CN1863545A (zh) 2003-08-15 2006-11-15 伊利诺斯大学理事会 Cupredoxin家族多肽在癌症治疗中的用途
UA97466C2 (ru) 2004-10-07 2012-02-27 Ананда Чакрабарти Транспортирующие соединения - производные купредоксина и способы их применения
MX2007014599A (es) 2005-05-20 2008-02-07 Univ Illinois Composiciones y metodos para el tratamiento de infeccion por vih con cupredoxina y citocromo c.
KR20080019615A (ko) 2005-05-20 2008-03-04 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신과 시토크롬으로 말라리아를 치료하기 위한조성물과 방법
AU2006269879A1 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death

Also Published As

Publication number Publication date
GEP20105022B (en) 2010-06-25
EP2263682A1 (en) 2010-12-22
US20080182782A1 (en) 2008-07-31
US20060292136A1 (en) 2006-12-28
US7888468B2 (en) 2011-02-15
EP1653990B1 (en) 2010-06-09
NZ545355A (en) 2009-10-30
DE602004027637D1 (de) 2010-07-22
AU2004266632A1 (en) 2005-03-03
WO2005018662A1 (en) 2005-03-03
EP1653990A1 (en) 2006-05-10
EA200600424A1 (ru) 2006-08-25
JP2007502818A (ja) 2007-02-15
US20140179617A1 (en) 2014-06-26
OA13308A (en) 2007-04-13
CA2535581A1 (en) 2005-03-03
US7491394B2 (en) 2009-02-17
US10421801B2 (en) 2019-09-24
ECSP066422A (es) 2006-11-24
IL173576A0 (en) 2006-07-05
KR20060098358A (ko) 2006-09-18
TNSN06059A1 (en) 2007-10-03
AP2006003537A0 (en) 2006-04-30
US20060040269A1 (en) 2006-02-23
ATE470672T1 (de) 2010-06-15
EA009897B1 (ru) 2008-04-28
BRPI0413574A (pt) 2006-10-17

Similar Documents

Publication Publication Date Title
NO20061168L (no) Andvendelse av polypeptider av cuperidoxinfamilien ved cancerterapi
MX2025001246A (es) Compuestos de piperidina 3-sustituidos para inhibicion del protooncogen-b de linfoma de linea b de casitas (cbl-b) y uso de un inhibidor de cbl-b en combinacion con una vacuna contra el cancer y/o con un virus oncolitico
WO2002076380A3 (en) Cytotoxic factors for modulating cell death
MX2025000627A (es) Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos
MX2023012981A (es) Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
CR20210415A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidoria en cdk2
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
WO2004092196A3 (en) Tie-2 modulators and methods of use
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
EA200600591A1 (ru) МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E
EP1481077A4 (en) MITOTIC KINESINE HEMMER
ATE446094T1 (de) Mitotische kinesin-hemmer
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
WO2004091480A3 (en) Tie-2 modulators and methods of use
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
PH12020552135A1 (en) Kdm1a inhibitors for the treatment of disease
DK1379510T3 (da) Aryl- og heteroarylurinstof Chk1-inhibitorer til anvendelse som radiosensibilisatorer og kemosensibilisatorer
BRPI0410078A (pt) uso de efetuadores de ciclases de glutaminila e glutamato
SG169224A1 (en) Method for treatment of tumors using nordihydrogualaretic acid derivatives
BRPI0318278B8 (pt) Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro
EA201100874A1 (ru) Соединения для лечения рака
NO20074944L (no) Heteroarylureaderivater anvendlige for inhibering av CHK1
WO2003075828A3 (en) Compounds useful in the treatment of cancer
PH12022550124A1 (en) Enzyme inhibitors
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application